 | Up a level |
Wahli, Murielle N; Hayoz, Stefanie; Hoch, Dennis; Ryser, Christoph O; Hoffmann, Michèle; Scherz, Amina; Schwacha-Eipper, Birgit; Häfliger, Simon; Wampfler, Julian; Berger, Martin D; Novak, Urban; Özdemir, Berna C (2023). The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex. Journal of cancer research and clinical oncology, 149(7), pp. 3847-3858. Springer 10.1007/s00432-022-04309-2
Schneider, Romano; Kraljević, Marko; Peterli, Ralph; Rohm, Theresa V; Bosch, Angela J T; Low, Andy J Y; Keller, Lena; AlAsfoor, Shefaa; Häfliger, Simon; Yilmaz, Bahtiyar; Peterson, Caspar J; Lazaridis, Ioannis I; Vonaesch, Pascale; Delko, Tarik; Cavelti-Weder, Claudia (2022). Roux-en-Y gastric bypass with a long versus a short biliopancreatic limb improves weight loss and glycemic control in obese mice. Surgery for obesity and related diseases, 18(11), pp. 1286-1297. Elsevier 10.1016/j.soard.2022.06.286
Häfliger, Simon; Seidel, Ann-Katrin; Schoch, Eric; Reichmann, Jan; Wild, Damian; Steinmann-Schwager, Stephanie; Pless, Miklos (2020). Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor. Case reports in oncology, 13(3), pp. 1373-1380. Karger 10.1159/000510334
Tiede, Stefanie; Meyer-Schaller, Nathalie; Kalathur, Ravi Kiran Reddy; Ivanek, Robert; Fagiani, Ernesta; Schmassmann, Philip; Stillhard, Patrick; Häfliger, Simon; Kraut, Norbert; Schweifer, Norbert; Waizenegger, Irene C; Bill, Ruben; Christofori, Gerhard (2018). The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis, 7(9), p. 73. Springer Nature 10.1038/s41389-018-0083-1
Eliçin, Olgun; Häfliger, Simon; Dorn, Patrick (May 2024). SAKK 16/18: QA and interim safety of immune-modulatory RT in resectable stage III(N2) NSCLC. Radiotherapy and oncology, 194(1), S1610-S1610. Elsevier
